Trial 4B-22-3


PhI-133/NCI 10483: Phase Ib trial of Erdafitinib combined with Enfortumab Vedotin following platinum and PD1/L1 inhibitors for metastatic urothelial carcinoma with FGFR2/3 genetic alterations

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anishka D'Souza, M.D.
Other Trial Staff:  Cheryl Kefauver, R.N., Monica Flores, D.M., Rubina Hassan, D.M., Lagrimas Ilagan, D.M., Roberto Tejada, Coordinator, Shamim Jhimlee, Coordinator, Honorina Enright, D.M., Bartolo Santos, Coordinator, Viviana Moreno, D.M., Sarah Chevalier, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.